{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:29:11Z","timestamp":1793957351225,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00393-026-01885-3","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:37:55Z","timestamp":1791920275000},"page":"734-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteoporose in der Rheumatologie\u00a0\u2013 Diagnostik, Risikobewertung und moderne Therapiestrategien","Osteoporosis in rheumatology\u2014Diagnostics, risk assessment and modern treatment strategies"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7911-4235","authenticated-orcid":false,"given":"Philipp","family":"Klemm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1885_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. Jama 285:785\u2013795","journal-title":"Jama"},{"key":"1885_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-024-01380-9","volume":"19","author":"P Hadji","year":"2024","unstructured":"Hadji\u00a0P, Esterberg\u00a0E, Oberm\u00fcller\u00a0D, Bartsch\u00a0R (2024) Bone evaluation study-2: update on the epidemiology of osteoporosis in Germany. Arch Osteoporos 19:26","journal-title":"Arch Osteoporos"},{"key":"1885_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00198-021-06051-w","volume":"33","author":"W B\u00f6cker","year":"2022","unstructured":"B\u00f6cker\u00a0W, Doobaree\u00a0IU, Khachatryan\u00a0A, Dornstauder\u00a0E, Bartsch\u00a0R, Worth\u00a0G, Singh\u00a0M, Kahangire\u00a0DA (2022) Fractures in untreated patients with osteoporosis in Germany: an InGef healthcare insurance database analysis. Osteoporos Int 33:77\u201386","journal-title":"Osteoporos Int"},{"key":"1885_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s00393-025-01624-0","volume":"84","author":"T Hoffmann","year":"2025","unstructured":"Hoffmann\u00a0T, Pflug\u00a0C, Schulze\u00a0W, Pfeil\u00a0A (2025) Systemic versus local demineralization in rheumatoid arthritis : Insights into the bone. Z Rheumatol 84:88\u201396","journal-title":"Z Rheumatol"},{"key":"1885_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41584-024-01120-w","volume":"20","author":"F Buttgereit","year":"2024","unstructured":"Buttgereit\u00a0F, Palmowski\u00a0A, Bond\u00a0M, Adami\u00a0G, Dejaco\u00a0C (2024) Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases. Nat Rev Rheumatol 20:417\u2013431","journal-title":"Nat Rev Rheumatol"},{"key":"1885_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00679","volume":"10","author":"F Coury","year":"2019","unstructured":"Coury\u00a0F, Peyruchaud\u00a0O, Machuca-Gayet\u00a0I (2019) Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases. Front Immunol 10:679","journal-title":"Front Immunol"},{"key":"1885_CR7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/acr.20423","volume":"63","author":"A Pfeil","year":"2011","unstructured":"Pfeil\u00a0A, Haugeberg\u00a0G, Hansch\u00a0A, Renz\u00a0DM, Lehmann\u00a0G, Malich\u00a0A, Wolf\u00a0G, Bottcher\u00a0J (2011) Value of digital X\u2011ray radiogrammetry in the assessment of inflammatory bone loss in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63:666\u2013674","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1885_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00223-005-0175-8","volume":"78","author":"J Bottcher","year":"2006","unstructured":"Bottcher\u00a0J, Pfeil\u00a0A, Mentzel\u00a0H, Kramer\u00a0A, Schafer\u00a0ML, Lehmann\u00a0G, Eidner\u00a0T, Petrovitch\u00a0A, Malich\u00a0A, Hein\u00a0G, Kaiser\u00a0WA (2006) Peripheral bone status in rheumatoid arthritis evaluated by digital X\u2011ray radiogrammetry and compared with multisite quantitative ultrasound. Calcif Tissue Int 78:25\u201334","journal-title":"Calcif Tissue Int"},{"key":"1885_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","volume":"8","author":"G Schett","year":"2012","unstructured":"Schett\u00a0G, Gravallese\u00a0E (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8:656\u2013664","journal-title":"Nat Rev Rheumatol"},{"key":"1885_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11926-012-0252-8","volume":"14","author":"IE Bultink","year":"2012","unstructured":"Bultink\u00a0IE, Vis\u00a0M, van der Horst-Bruinsma\u00a0IE, Lems\u00a0WF (2012) Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep 14:224\u2013230","journal-title":"Curr Rheumatol Rep"},{"key":"1885_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41584-022-00764-w","volume":"18","author":"B So\u00f3s","year":"2022","unstructured":"So\u00f3s\u00a0B, Szentp\u00e9tery \u00c1, Raterman\u00a0HG, Lems\u00a0WF, Bhattoa\u00a0HP, Szekanecz\u00a0Z (2022) Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases. Nat Rev Rheumatol 18:249\u2013257","journal-title":"Nat Rev Rheumatol"},{"key":"1885_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle\u00a0WJ, Simonet\u00a0WS, Lacey\u00a0DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342","journal-title":"Nature"},{"key":"1885_CR13","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI60975","volume":"122","author":"U Harre","year":"2012","unstructured":"Harre\u00a0U, Georgess\u00a0D, Bang\u00a0H, Bozec\u00a0A, Axmann\u00a0R, Ossipova\u00a0E, Jakobsson\u00a0PJ, Baum\u00a0W, Nimmerjahn\u00a0F, Szarka\u00a0E, Sarmay\u00a0G, Krumbholz\u00a0G, Neumann\u00a0E, Toes\u00a0R, Scherer\u00a0HU, Catrina\u00a0AI, Klareskog\u00a0L, Jurdic\u00a0P, Schett\u00a0G (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J\u00a0Clin Invest 122:1791\u20131802","journal-title":"J Clin Invest"},{"key":"1885_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra\u00a0D, Stolina\u00a0M, Polzer\u00a0K, Zwerina\u00a0J, Ominsky\u00a0MS, Dwyer\u00a0D, Korb\u00a0A, Smolen\u00a0J, Hoffmann\u00a0M, Scheinecker\u00a0C, van der Heide\u00a0D, Landewe\u00a0R, Lacey\u00a0D, Richards\u00a0WG, Schett\u00a0G (2007) Dickkopf\u20111 is a master regulator of joint remodeling. Nat Med 13:156\u2013163","journal-title":"Nat Med"},{"key":"1885_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41584-025-01323-9","volume":"22","author":"M Rauner","year":"2026","unstructured":"Rauner\u00a0M, Bozec\u00a0A (2026) Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis. Nat Rev Rheumatol 22:42\u201361","journal-title":"Nat Rev Rheumatol"},{"key":"1885_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1835307","volume":"17","author":"N Schulz","year":"2026","unstructured":"Schulz\u00a0N, van Wijnen\u00a0P, Wilhelmi\u00a0T, M\u00fcller-Ladner\u00a0U, Lange\u00a0U, Klemm\u00a0P (2026) Skeletal effects of JAK\u00a01\/2 inhibition versus IL\u20116 receptor blockade in rheumatoid arthritis: a\u00a0post hoc comparative cohort analysis based on two prospective observational studies. Front Pharmacol 17:1835307","journal-title":"Front Pharmacol"},{"key":"1885_CR17","unstructured":"DVO-Leitlinie (2023) Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften 2023 - Prophylaxe, Diagnostik und Therapie der Osteoporose. https:\/\/dv-osteologie.org\/uploads\/Leitlinie%202023%20-%20Letzter%20Stand%20der%20Dokumente,%2012102023\/Leitlinie%2031102023\/DVO%20Leitlinie%20zur%20Diagnostik%20und%20Therapie%20der%20Osteoporose%20Version%2021%202023%20(002)pdf"},{"key":"1885_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s001170050495","volume":"39","author":"D Felsenberg","year":"1999","unstructured":"Felsenberg\u00a0D, Gowin\u00a0W (1999) Bone densitometry by dual energy methods. Radiologe 39:186\u2013193","journal-title":"Radiologe"},{"key":"1885_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF00197459","volume":"23","author":"M Jergas","year":"1994","unstructured":"Jergas\u00a0M, Uffmann\u00a0M, Escher\u00a0H, Gl\u00fcer\u00a0CC, Young\u00a0KC, Grampp\u00a0S, K\u00f6ster\u00a0O, Genant\u00a0HK (1994) Interobserver variation in the detection of osteopenia by radiography and comparison with dual X\u2011ray absorptiometry of the lumbar spine. Skeletal Radiol 23:195\u2013199","journal-title":"Skeletal Radiol"},{"key":"1885_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","volume":"36","author":"HP Bhattoa","year":"2025","unstructured":"Bhattoa\u00a0HP, Vasikaran\u00a0S, Trifonidi\u00a0I, Kapoula\u00a0G, Lombardi\u00a0G, J\u00f8rgensen\u00a0NR, Pikner\u00a0R, Miura\u00a0M, Chapurlat\u00a0R, Hiligsmann\u00a0M, Haarhaus\u00a0M, Evenepoel\u00a0P, J\u00f8rgensen\u00a0HS, Herrmann\u00a0M, Kaufman\u00a0JM, Clark\u00a0P, Tuzun \u015e, Al-Daghri\u00a0N, Silverman\u00a0S, Alokail\u00a0MS, Ormarsd\u00f3ttir\u00a0S, Yerro\u00a0MCP, Matijevic\u00a0R, Laslop\u00a0A, da Silva Rosa\u00a0MMC, Zakraoui\u00a0L, Burlet\u00a0N, McCloskey\u00a0E, Harvey\u00a0NC, Radermecker\u00a0RP, Fusaro\u00a0M, Torre\u00a0C, Kanis\u00a0JA, Rizzoli\u00a0R, Reginster\u00a0JY, Makris\u00a0K, Cavalier\u00a0E (2025) Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Osteoporos Int 36:579\u2013608","journal-title":"Osteoporos Int"},{"key":"1885_CR21","doi-asserted-by":"crossref","unstructured":"Kanis JA, Johansson H, McCloskey EV, Liu E, Schini M, Vandenput L, \u00c5kesson KE, Anderson FA, Azagra R, Bager CL, Beaudart C, Bischoff-Ferrari HA, Biver E, Bruy\u00e8re O, Cauley JA, Center JR, Chapurlat R, Christiansen C, Cooper C, Crandall CJ, Cummings SR, da Silva JAP, Dawson-Hughes B, Diez-Perez A, Dufour AB, Eisman JA, Elders PJM, Ferrari S, Fujita Y, Fujiwara S, Gl\u00fcer CC, Goldshtein I, Goltzman D, Gudnason V, Hall J, Hans D, Hoff M, Hollick RJ, Huisman M, Iki M, Ish-Shalom S, Jones G, Karlsson MK, Khosla S, Kiel DP, Koh WP, Koromani F, Kotowicz MA, Kr\u00f6ger H, Kwok T, Lamy O, Langhammer A, Larijani B, Lippuner K, McGuigan FEA, Mellstr\u00f6m D, Merlijn T, Nguyen TV, Nordstr\u00f6m A, Nordstr\u00f6m P, TW ON, Obermayer-Pietsch B, Ohlsson C, Orwoll ES, Pasco JA, Rivadeneira F, Schott AM, Shiroma EJ, Siggeirsdottir K, Simonsick EM, Sornay-Rendu E, Sund R, Swart K, Szulc P, Tamaki J, Torgerson DJ, van Schoor NM, van Staa TP, Vila J, Wright NC, Yoshimura N, Zillikens MC, Zwart M, Harvey NC, Lorentzon M, Leslie WD (2025) Rheumatoid arthritis and subsequent fracture risk: an individual person meta-analysis to update FRAX. Osteoporos Int\u00a036:653\u2013671","DOI":"10.1007\/s00198-025-07397-1"},{"key":"1885_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/acr.25466","volume":"77","author":"CA Jones","year":"2025","unstructured":"Jones\u00a0CA, Guy\u00a0P, Xie\u00a0H, Sayre\u00a0EC, Zhao\u00a0K, Lacaille\u00a0D (2025) Incidence of and Risk of Mortality After Hip Fractures in Rheumatoid Arthritis Relative to the General Population. Arthritis Care Res (Hoboken) 77:604\u2013613","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1885_CR23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5414\/NHX02324","volume":"52","author":"AO Pfeil","year":"2023","unstructured":"Pfeil\u00a0AO, Wolf\u00a0P, Wolf\u00a0G (2023) Die Behandlung der Osteoporose bei chronischer Niereninsuffizienz: Herausforderungen und Strategien 2023. Nieren- und Hochdruckerkrankungen 52:370\u2013376","journal-title":"Nieren- und Hochdruckerkrankungen"},{"key":"1885_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00774-023-01452-9","volume":"41","author":"K Chiba","year":"2023","unstructured":"Chiba\u00a0K, Iwamoto\u00a0N, Watanabe\u00a0K, Shiraishi\u00a0K, Saito\u00a0K, Okubo\u00a0N, Kawakami\u00a0A, Osaki\u00a0M (2023) Denosumab improves bone mineral density and microarchitecture in rheumatoid arthritis: randomized controlled trial by HR-pQCT. J\u00a0Bone Miner Metab 41:797\u2013806","journal-title":"J Bone Miner Metab"},{"key":"1885_CR25","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt\u00a0P, Faouzi\u00a0M, Buclin\u00a0T, Lamy\u00a0O (2021) Fractures After Denosumab Discontinuation: A\u00a0Retrospective Study of 797 Cases. J\u00a0Bone Miner Res 36:1717\u20131728","journal-title":"J Bone Miner Res"},{"key":"1885_CR26","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman\u00a0F, Kendler\u00a0DL, Langdahl\u00a0BL, Leder\u00a0BZ, Lewiecki\u00a0EM, Miyauchi\u00a0A, Rojeski\u00a0M, McDermott\u00a0M, Oates\u00a0MK, Milmont\u00a0CE, Libanati\u00a0C, Ferrari\u00a0S (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33:1243\u20131256","journal-title":"Osteoporos Int"},{"key":"1885_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/mr\/roac059","volume":"33","author":"T Mochizuki","year":"2023","unstructured":"Mochizuki\u00a0T, Yano\u00a0K, Ikari\u00a0K, Hiroshima\u00a0R, Okazaki\u00a0K (2023) Comparison of romosozumab versus denosumab treatment on bone mineral density after 1\u00a0year in rheumatoid arthritis patients with severe osteoporosis: A\u00a0randomized clinical pilot study. Mod Rheumatol 33:490\u2013495","journal-title":"Mod Rheumatol"},{"key":"1885_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.afos.2021.08.001","volume":"7","author":"T Mochizuki","year":"2021","unstructured":"Mochizuki\u00a0T, Yano\u00a0K, Ikari\u00a0K, Okazaki\u00a0K (2021) Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6\u00a0months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study. Osteoporos Sarcopenia 7:110\u2013114","journal-title":"Osteoporos Sarcopenia"},{"key":"1885_CR29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder\u00a0BZ, Tsai\u00a0JN, Uihlein\u00a0AV, Wallace\u00a0PM, Lee\u00a0H, Neer\u00a0RM, Burnett-Bowie\u00a0SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155","journal-title":"Lancet"},{"key":"1885_CR30","doi-asserted-by":"crossref","unstructured":"Oelzner P, Mueller PH, Hoffmann T, Schwabe A, Lehmann G, Eidner T, Wolf G, Pfeil A (2024) Significant decrease of osteoporosis and osteoporotic fractures in rheumatoid arthritis within a\u00a0period of 24\u00a0years: experiences of a\u00a0single centre. RMD Open\u00a010","DOI":"10.1136\/rmdopen-2024-004564"},{"key":"1885_CR31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00296-018-4226-7","volume":"39","author":"A Pfeil","year":"2019","unstructured":"Pfeil\u00a0A, Nussbaum\u00a0A, Renz\u00a0DM, Jung\u00a0C, Oelzner\u00a0P, Malich\u00a0A, Wolf\u00a0G, Bottcher\u00a0J (2019) Inhibition of periarticular bone loss is associated with clinical remission and ACR70-Response in rheumatoid arthritis. Rheumatol Int 39:637\u2013645","journal-title":"Rheumatol Int"},{"key":"1885_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-025-01410-9","volume":"116","author":"N Schulz","year":"2025","unstructured":"Schulz\u00a0N, Asendorf\u00a0T, van Wijnen\u00a0P, Wilhelmi\u00a0T, M\u00fcller-Ladner\u00a0U, Lange\u00a0U, Klemm\u00a0P (2025) Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A\u00a0Monocentric Observational Study. Calcif Tissue Int 116:101","journal-title":"Calcif Tissue Int"},{"key":"1885_CR33","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/art.42617","volume":"75","author":"D Simon","year":"2023","unstructured":"Simon\u00a0D, Minopoulou\u00a0I, Kemenes\u00a0S, Bayat\u00a0S, Tascilar\u00a0K, Mutlu\u00a0MY, Valor-M\u00e9ndez\u00a0L, Kr\u00f6nke\u00a0G, Hueber\u00a0AJ, Schett\u00a0G, Kleyer\u00a0A (2023) Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial. Arthritis Rheumatol 75:1923\u20131934","journal-title":"Arthritis Rheumatol"},{"key":"1885_CR34","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2665-9913(26)00072-X","volume":"8","author":"F Buttgereit","year":"2026","unstructured":"Buttgereit\u00a0F, Tam\u00a0LS (2026) Glucocorticoid treatment in patients with inflammatory rheumatic diseases: current practice and open questions. Lancet Rheumatol 8:e389\u2013e400","journal-title":"Lancet Rheumatol"},{"key":"1885_CR35","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1093\/rheumatology\/kead088","volume":"62","author":"A Palmowski","year":"2023","unstructured":"Palmowski\u00a0A, Nielsen\u00a0SM, Boyadzhieva\u00a0Z, Schneider\u00a0A, Pankow\u00a0A, Hartman\u00a0L, Da Silva\u00a0JAP, Kirwan\u00a0J, Wassenberg\u00a0S, Dejaco\u00a0C, Christensen\u00a0R, Boers\u00a0M, Buttgereit\u00a0F (2023) Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 62:2652\u20132660","journal-title":"Rheumatology (Oxford)"},{"key":"1885_CR36","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ard.2025.10.008","volume":"85","author":"A Palmowski","year":"2026","unstructured":"Palmowski\u00a0A, Beenken\u00a0AE, Pankow\u00a0A, Oldenkott\u00a0J, K\u00e4ding\u00a0H, Wiebe\u00a0E, Boyadzhieva\u00a0Z, Matteson\u00a0EL, Minopoulou\u00a0I, Witte\u00a0T, Simon\u00a0D, Boers\u00a0M, Kleyer\u00a0A, Buttgereit\u00a0F (2026) Confounding by indication in observational studies investigating glucocorticoid-associated adverse events in patients with rheumatoid arthritis: a systematic literature review including an assessment of E\u2011values. Ann Rheum Dis 85:580\u2013583","journal-title":"Ann Rheum Dis"},{"key":"1885_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03083-x","volume":"25","author":"A Palmowski","year":"2023","unstructured":"Palmowski\u00a0A, Boyadzhieva\u00a0Z, Nielsen\u00a0SM, Muche\u00a0B, Hermann\u00a0S, Boers\u00a0M, Bliddal\u00a0H, Christensen\u00a0R, Wiebe\u00a0E, Buttgereit\u00a0F (2023) Sex and age do not modify the association between glucocorticoids and bone mineral density in patients with rheumatoid arthritis: a\u00a0cross-sectional study. Arthritis Res Ther 25:98","journal-title":"Arthritis Res Ther"},{"key":"1885_CR38","doi-asserted-by":"crossref","unstructured":"Palmowski A, Haugegaard T, Hafstr\u00f6m I, Bliddal H, Oldenkott J, Wassenberg S, Choy E, Kirwan J, Christensen R, Boers M, Buttgereit F (2026) Changes in bone mineral density and fractures during 2\u00a0years of low-dose glucocorticoid treatment for rheumatoid arthritis: a\u00a0systematic literature review and individual participant data meta-analysis. RMD Open\u00a012","DOI":"10.1136\/rmdopen-2025-006615"},{"key":"1885_CR39","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.mayocp.2023.12.008","volume":"99","author":"A Palmowski","year":"2024","unstructured":"Palmowski\u00a0A, Schmajuk\u00a0G, Yazdany\u00a0J, Katz\u00a0P, Li\u00a0J, Stovall\u00a0R, Kersey\u00a0E, Nielsen\u00a0SM, Christensen\u00a0R, Bliddal\u00a0H, Boyadzhieva\u00a0Z, Schneider\u00a0U, Alexander\u00a0T, Muche\u00a0B, Hermann\u00a0S, Wiebe\u00a0E, Buttgereit\u00a0F (2024) Proton Pump Inhibitor Use and Bone Health in Patients With Rheumatic Diseases: A\u00a0Cross-Sectional Study. Mayo Clin Proc 99:1046\u20131057","journal-title":"Mayo Clin Proc"},{"key":"1885_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.70055","volume":"28","author":"M Zeng","year":"2025","unstructured":"Zeng\u00a0M, Lee\u00a0YH, Wang\u00a0SI, Palmowski\u00a0A, Chu\u00a0WM, Buttgereit\u00a0F (2025) Fracture Risk Linked to Proton Pump Inhibitors Versus H2 Receptor Antagonists in Autoimmune Rheumatic and Gastrointestinal Disease Patients. Int J Rheum Dis 28:e70055","journal-title":"Int J Rheum Dis"},{"key":"1885_CR41","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1002\/jbmr.4683","volume":"37","author":"I Hoffmann","year":"2022","unstructured":"Hoffmann\u00a0I, Shojaa\u00a0M, Kohl\u00a0M, von Stengel\u00a0S, Becker\u00a0C, Gosch\u00a0M, Jakob\u00a0F, Kerschan-Schindl\u00a0K, Kladny\u00a0B, Clausen\u00a0J, Lange\u00a0U, Middeldorf\u00a0S, Peters\u00a0S, Schoene\u00a0D, Sieber\u00a0C, Tholen\u00a0R, Thomasius\u00a0F, Bischoff-Ferrari\u00a0HA, Uder\u00a0M, Kemmler\u00a0W (2022) Exercise Reduces the Number of Overall and Major Osteoporotic Fractures in Adults. Does Supervision Make a Difference? Systematic Review and Meta-Analysis. J\u00a0Bone Miner Res 37:2132\u20132148","journal-title":"J Bone Miner Res"},{"key":"1885_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00393-024-01609-5","volume":"84","author":"U Lange","year":"2025","unstructured":"Lange\u00a0U, Rei\u00dfhauer\u00a0A, Kemmler\u00a0W (2025) Quintessence of the new guidelines on physical training and fracture prophylaxis. Z Rheumatol 84:97\u2013106","journal-title":"Z Rheumatol"},{"key":"1885_CR43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/a-2067-4323","volume":"32","author":"M Shojaa","year":"2023","unstructured":"Shojaa\u00a0M, Hoffmann\u00a0I, Kohl\u00a0M, von Stengel\u00a0S, Becker\u00a0C, Gosch\u00a0M, Jakob\u00a0F, Kerschan-Schindl\u00a0K, Kladny\u00a0B, Lange\u00a0U, Peters\u00a0S, Sch\u00f6ne\u00a0D, Sieber\u00a0C, Thomasius\u00a0F, Uder\u00a0M, Kemmler\u00a0W (2023) Exercise Effects on the Reduction of Low-Traumatic and Major Osteoporotic Fractures in Adults. Systematic Review and Meta-Analysis. Osteologie 32:156","journal-title":"Osteologie"},{"key":"1885_CR44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/a-2075-7106","volume":"32","author":"R Mohebbi","year":"2023","unstructured":"Mohebbi\u00a0R, von Stengel\u00a0S, Kohl\u00a0M, Jakob\u00a0F, Kerschan-Schindl\u00a0K, Lange\u00a0U, Peters\u00a0S, Sch\u00f6ne\u00a0D, Thomasius\u00a0F, Becker\u00a0C, Kladny\u00a0B, Kemmler\u00a0W (2023) Training Aims and Risk Categorization in The Area of Exercise and Fracture Prevention. Targets for Individualized Training Programs. Osteologie 32:166\u2013+","journal-title":"Osteologie"},{"key":"1885_CR45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1055\/a-2057-0273","volume":"32","author":"S von Stengel","year":"2023","unstructured":"von Stengel\u00a0S, Kohl\u00a0M, Jakob\u00a0F, Kerschan-Schindl\u00a0K, Lange\u00a0U, Peters\u00a0S, Thomasius\u00a0F, Uder\u00a0M, Shojaa\u00a0M, Kemmler\u00a0W (2023) Recommendations on exercise methods for bone strengthening. Osteologie 32:176","journal-title":"Osteologie"},{"key":"1885_CR46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/a-2110-7105","volume":"32","author":"D Schoene","year":"2023","unstructured":"Schoene\u00a0D, Gross\u00a0M, von Stengel\u00a0S, Kohl\u00a0M, Kladny\u00a0B, Gosch\u00a0M, Sieber\u00a0CC, Peters\u00a0S, Kiesswetter\u00a0E, Becker\u00a0C, Kemmler\u00a0W (2023) Recommendations on Physical Exercise and Fall Prevention in Older Community-Dwelling Adults. Osteologie 32:183","journal-title":"Osteologie"},{"key":"1885_CR47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00393-024-01495-x","volume":"83","author":"A Pfeil","year":"2024","unstructured":"Pfeil\u00a0A, Lange\u00a0U (2024) Update on the DVO Guideline 2023 \u201cProphylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50\u201d-What\u2019s new for rheumatology? Z Rheumatol 83:401\u2013406","journal-title":"Z Rheumatol"},{"key":"1885_CR48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0042-118878","volume":"42","author":"A Pfeil","year":"2017","unstructured":"Pfeil\u00a0A, Lehmann\u00a0G, B\u00f6ttcher\u00a0J, Reinhardt\u00a0L, Oelzner\u00a0P, Wolf\u00a0G, Renz\u00a0DM (2017) Measurement of Bone Mineral Density in Daily Practice. Aktuelle Rheumatologie 42:211\u2013216","journal-title":"Aktuelle Rheumatologie"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01885-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01885-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01885-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:00:10Z","timestamp":1793955610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01885-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1885"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01885-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"29 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Klemm\n                      : A.\u00a0Finanzielle Interessen: UCB: Reisef\u00f6rderung Kongress EULAR und DGRh. \u2013\u00a0Gedeon Richter: 1\u202f\u00d7\u2009Vortrag.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: \u00c4rztlicher Direktor der Abteilung Osteologie und Physikalische Medizin, Rheumazentrum, Campus Kerckhoff der Justus-Liebig-Universit\u00e4t Gie\u00dfen, Kerckhoff-Klinik, Benekestr.\u00a02\u20138, 61231 Bad Nauheim | Leiter der Kommission Osteologie der DGRh.\n                      A.\u00a0Pfeil\n                      : A.\u00a0Finanzielle Interessen: A.\u00a0Pfeil  war als Referent f\u00fcr UCB t\u00e4tig und erhielt hierf\u00fcr ein Vortragshonorar. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Leiter des Rheumazentrum (G-BA-Regeln) sowie der Sektion Rheumatologie und Osteologie an der Klinik f\u00fcr Innere Medizin\u00a0III, Universit\u00e4tsklinikum Jena; Leitung der Spezialsprechstunde Vaskulitis und Autoinflammation; Leiter des Osteologischen Schwerpunktzentrums; Leiter des Osteologischen Studienzentrums | A. Pfeil hielt im Rahmen seiner Dienstaufgabe als Leiter des Rheumazentrums (nach G-BA-Regeln) des Universit\u00e4tsklinikums Jena Vortr\u00e4ge f\u00fcr die Gedeon Richter Pharma GmbH und Samsung Bioepis.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}